Research to Optimizing Pharmacotherapy for Neurological Disorders

Sasha Lindstrom^*
*Correspondence: Sasha Lindstrom, Department of Neurology, University of Dallas, Dallas, USA, Email:

Introduction

Neurological disorders encompass a wide range of conditions that affect the nervous system, such as Parkinson's disease, multiple sclerosis, epilepsy, and Alzheimer's disease. Patients with these disorders often require complex medication regimens to manage their symptoms and slow disease progression. However, drug-related problems are common in this patient population and can lead to adverse drug events, poor treatment outcomes, and increased healthcare costs. To address these challenges, a clinical pharmacist integrated approach plays a crucial role in identifying, preventing, and resolving DRPs in patients with neurological disorders. This approach involves comprehensive medication reviews, interdisciplinary collaboration, patient education and ongoing monitoring. By employing this approach, healthcare professionals can optimize medication therapy and improve patient outcomes. A clinical pharmacist conducts comprehensive medication reviews for patients with neurological disorders to assess the rate and pattern of DRPs. These reviews involve evaluating the appropriateness of medication therapy, identifying potential drug interactions, ensuring dosage adjustments for patients with renal or hepatic impairment, and considering individual patient factors. By reviewing medication regimens holistically, pharmacists can identify and resolve DRPs such as inappropriate drug selection, suboptimal dosing, medication duplications, and non-adherence [1].

Description

Collaboration between clinical pharmacists and other healthcare professionals, including neurologists, nurses, and primary care physicians, is crucial in assessing the rate and pattern of DRPs in patients with neurological disorders. Regular communication and interdisciplinary meetings allow for comprehensive discussions about medication therapy, potential adverse effects, and alternative treatment options. This collaboration promotes a team-based approach, ensuring that all healthcare providers are aware of the patient's medication-related challenges and work together to optimize treatment outcomes. Clinical pharmacists play a vital role in educating patients with neurological disorders about their medications. They provide information on the purpose of each medication, potential side effects, and strategies to enhance medication adherence. By promoting patient understanding and involvement in their treatment, pharmacists empower patients to take an active role in managing their neurological disorder and reduce the likelihood of DRPs. Patient education also involves counseling on lifestyle modifications, such as dietary considerations and exercise, which can complement medication therapy and improve overall health [2].

Regular follow-up visits and ongoing monitoring are essential components of a clinical pharmacist integrated approach to assessing DRPs in patients with neurological disorders. Pharmacists track medication adherence, monitor treatment response, assess for adverse drug reactions, and adjust therapy as needed. Through this proactive monitoring, pharmacists can identify emerging DRPs and intervene in a timely manner. Additionally, they collaborate with patients and healthcare providers to ensure effective communication and address any concerns or questions that may arise during the course of treatment. Through comprehensive medication reviews, clinical pharmacists optimize medication therapy for patients with neurological disorders. They identify opportunities to streamline regimens, reduce polypharmacy, and ensure appropriate dosing. By tailoring treatment plans to individual patient needs, pharmacists improve the efficacy and tolerability of medications, leading to better disease management. The integration of clinical pharmacists in the management of patients with neurological disorders can lead to cost savings. By preventing DRPs, reducing hospital readmissions, and enhancing treatment outcomes, pharmacists contribute to more efficient healthcare utilization. This approach not only benefits individual patients but also reduces the overall burden on the healthcare system [3].

In patients with neurological disorders, drug-related problems are common and can significantly impact treatment outcomes. A clinical pharmacist integrated approach offers a comprehensive strategy for assessing the rate and pattern of DRPs in these patients. Through comprehensive medication reviews, interdisciplinary collaboration, patient education, and ongoing monitoring, clinical pharmacists play a vital role in optimizing medication therapy, improving patient safety, and enhancing treatment outcomes. By embracing this approach, healthcare professionals can address the complex medication challenges faced by patients with neurological disorders and provide individualized care that maximizes the benefits of pharmacotherapy. Ultimately, a clinical pharmacist integrated approach contributes to better management of neurological disorders, leading to improved quality of life for patients. Neurological disorders encompass a broad spectrum of conditions affecting the central and peripheral nervous systems. These disorders, which include epilepsy, Parkinson's disease, multiple sclerosis, and Alzheimer's disease, often require complex pharmacological treatment regimens to manage symptoms and slow disease progression. However, the use of multiple medications and the complexity of these conditions can lead to drugrelated problems that may compromise patient outcomes and quality of life. To optimize patient care and minimize the risks associated with pharmacotherapy, clinical pharmacists play a crucial role in identifying, assessing, and addressing DRPs. Clinical pharmacists review patients' medication histories to identify potential DRPs, such as drug interactions, duplication of therapy, or inappropriate dosing [4].

They assess the medications' appropriateness, adherence, and patient understanding. By conducting a comprehensive medication review, clinical pharmacists analyze the pharmacokinetic and pharmacodynamic properties of each drug to evaluate their effectiveness and potential for adverse effects. They consider factors such as drug-drug interactions, drug-food interactions, and drug-disease interactions that may exacerbate or compromise the treatment of neurological disorders. Clinical pharmacists perform a thorough evaluation of patients' clinical parameters, including physical, neurological, and psychological assessments. This evaluation helps identify any changes or deteriorations that may be related to drug therapy or the underlying neurological disorder itself. Based on the medication history, comprehensive medication review, and patient evaluation, clinical pharmacists systematically identify DRPs, including adverse drug reactions, suboptimal drug selection or dosing, medication non-adherence, and the need for additional therapies or interventions. They also identify potential gaps in therapy and patient education needs. Clinical pharmacists work collaboratively with other healthcare professionals, including neurologists, nurses, and social workers, to address the identified DRPs. They engage in interdisciplinary discussions, contribute to treatment decisions, and propose appropriate interventions to optimize therapy and patient outcomes. Clinical pharmacists play a vital role in educating patients and caregivers about their medications, including drug administration, potential side effects, and the importance of adherence [5].

Conclusion

They provide counseling regarding lifestyle modifications, drug interactions to avoid, and strategies to manage potential adverse effects. Accurate documentation of DRPs, interventions, and patient outcomes is a critical aspect of the clinical pharmacist's role. They maintain detailed records, enabling future analysis and facilitating research into optimizing pharmacotherapy for neurological disorders. In patients with neurological disorders, the optimization of pharmacotherapy requires a multidimensional approach to identify and address DRPs. Clinical pharmacists, with their specialized knowledge and training, are uniquely positioned to play a vital role in assessing the rate and pattern of DRPs. Through medication history assessment, comprehensive medication reviews, patient evaluations, and collaboration with the interdisciplinary team, clinical pharmacists can identify and resolve DRPs effectively. Their involvement in patient education and counseling empowers patients to actively participate in their treatment and enhances medication adherence. The integration of clinical pharmacists into healthcare teams can significantly contribute to the improved management of neurological disorders, leading to enhanced patient outcomes and a better quality of life. By continuously evaluating and addressing DRPs, clinical pharmacists contribute to the optimization of pharmacotherapy, ensuring safer and more effective treatment options for patients with neurological disorders.

Acknowledgement

None

Conflict of Interest

None

References

1. Ramesh, Geeta, Andrew G. MacLean and Mario T. Philipp. "Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain."Mediat Inflamm2013 (2013).

Google Scholar, Crossref, Indexed at

2. Sturdevant, Christa Buckheit, Sarah B. Joseph, Gretja Schnell and Richard W. Price, et al. "Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection."PLoS Pathogens11 (2015): e1004720.

Google Scholar, Crossref, Indexed at

3. Hagberg, Lars, Paola Cinque, Magnus Gisslen and Bruce J. Brew, et al. "Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection."AIDS Res Ther7 (2010): 1-12.

Google Scholar, Crossref, Indexed at

4. Gaetani, Lorenzo, Kaj Blennow, Paolo Calabresi and Massimiliano Di Filippo, et al. "Neurofilament light chain as a biomarker in neurological disorders."J Neurol Neurosurg Psychiatry90 (2019): 870-881.

Google Scholar, Crossref, Indexed at

5. Tortelli, R., M. Copetti, M. Ruggieri and R. Cortese, et al. "Cerebrospinal fluid neurofilament light chain levels: Marker of progression to generalized amyotrophic lateral sclerosis."Eur J Neurol22 (2015): 215-218.

Google Scholar, Crossref, Indexed at